Eric Lefkofsky
Eric Lefkofsky is the founder and CEO of Tempus, a company he established in 2015. He has been instrumental in leading Tempus to become a leader in artificial intelligence and precision medicine, focusing on leveraging data to improve patient outcomes, particularly in oncology. Under his leadership, Tempus has built a vast library of clinical and molecular data and an operating system to make that data accessible and useful for personalized patient care. Eric Lefkofsky co-founded InnerWorkings in 2001, a print procurement services firm that went public in 2006. In 2005, he co-founded Echo Global Logistics, a freight logistics company that also went public in 2006. Lefkofsky is widely recognized as the co-founder of Groupon in 2007, serving as CEO from 2013 to 2016. In 2011, he was named "Entrepreneur of the Year" by Ernst & Young. Since 2015, Lefkofsky has been the founder and CEO of Tempus AI, a company focused on advancing precision medicine through artificial intelligence. His work at Tempus reflects a personal mission to improve patient outcomes through data-driven solutions in healthcare.
Career Milestones
- Eric Lefkofsky co-founded InnerWorkings in 2001, a print procurement services firm that went public in 2006.
- In 2005, he co-founded Echo Global Logistics, a freight logistics company that went public in 2006.
- He co-founded Groupon in 2007 and served as CEO from 2013 to 2016, helping grow it into a global e-commerce platform.
- In 2011, Lefkofsky was named "Entrepreneur of the Year" by Ernst & Young.
- In 2015, he founded Tempus, an AI-driven precision medicine company focused on improving patient outcomes through data and technology.
About Tempus
Tempus, founded in 2015, is a health technology company leveraging AI and a vast library of clinical and molecular data to advance precision medicine. They help physicians, researchers, and pharmaceutical companies by providing AI-enabled diagnostics, personalized treatment plans, and tools for drug discovery and clinical trial matching, primarily in oncology, but also expanding to other areas like neuropsychiatry and cardiology. Core features include genomic sequencing, AI-powered insights, and platforms like Tempus One for clinical assistance. Benefits include improved patient outcomes through data-driven decisions and accelerated therapeutic development.